Control siRNA duplex Beta-actin (human), 5 nmol

Control siRNA duplex Beta-actin (human), 5 nmol

Control siRNA duplex Cdk-1 (human), 5 nmol

Control siRNA duplex Cdk-1 (human), 5 nmol

Control siRNA duplex Eg-5 (human), 5 nmol

489,09 RON
Control siRNA duplex Eg-5 (human), 5 nmol, Cod Catalog Eurogentec: SR-CL005-005
SKU
EUR_SR-CL005-005

In order to monitor your siRNA experiment conditions, Eurogentec provides siRNA control duplexes.
As for any valid experiment, negative and positive controls are necessary.

Control siRNA duplex Eg-5 is a positive control available in 5 nmol final quantity. It contains 1 siRNA duplex.
All siRNA control duplexes are IEX-HPLC purified and 100 % MALDI-TOF Mass Spectrometry controlled.
The sequences are validated and published.

RNA interference is licensed under European Patents 1144623, 1214945 and foreign equivalents from Alnylam Pharmaceuticals, Inc., Cambridge, USA and is provided only for use in academic and commercial research (excluding the evaluation or characterization of this product as the potential basis for a siRNA-based drug) and not for any other commercial purposes. Information about licenses for commercial use (including discovery and development of siRNA-based drugs) is available from Alnylam Pharmaceuticals, Inc., 300 Third Street, Cambridge, MA 02142, USA.

 

Mai multe informatii
Price 411,00 RON (preturile sunt fara TVA)
Description

In order to monitor your siRNA experiment conditions, Eurogentec provides siRNA control duplexes.
As for any valid experiment, negative and positive controls are necessary.

Control siRNA duplex Eg-5 is a positive control available in 5 nmol final quantity. It contains 1 siRNA duplex.
All siRNA control duplexes are IEX-HPLC purified and 100 % MALDI-TOF Mass Spectrometry controlled.
The sequences are validated and published.

RNA interference is licensed under European Patents 1144623, 1214945 and foreign equivalents from Alnylam Pharmaceuticals, Inc., Cambridge, USA and is provided only for use in academic and commercial research (excluding the evaluation or characterization of this product as the potential basis for a siRNA-based drug) and not for any other commercial purposes. Information about licenses for commercial use (including discovery and development of siRNA-based drugs) is available from Alnylam Pharmaceuticals, Inc., 300 Third Street, Cambridge, MA 02142, USA.